Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.
inotrem has raised €58M across 2 funding rounds from 3 investors, most recently a round in Dec 2020. Based in Paris, France; founded 2013; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2020-12-02 | Other | €19M | Fountain Healthcare Partners | View deal → |
| 2019-10-01 | Series B | €39M | Invus,Morningside Group | View deal → |
